Guidance for differentiating anaphylaxis from acute stress response for vaccine providers and Emergency Departments
Anaphylaxis following immunisation is extremely rare but can be life-threatening if not managed effectively. There are many conditions with similar presentations to anaphylaxis without being true anaphylaxis (eg. vasovagal, anxiety, vocal cord dysfunction) which can make the diagnosis difficult.
The Department of Health and the VicSIS网络 have put together Guidance for differentiating anaphylaxis from acute stress response for vaccine providers and Emergency Departments. This helpful resource provides a comparison of signs and symproms, as well as highlights the importance of measuring tryptase levels in patients with suspected anaphylaxis.
This guidance can be found in the resources section of the below reference page:
New immunisation reference page: COVID-19 vaccines in people with immunocompromise
Despite vaccination being recommended, there is currently minimal data on the safety and efficacy of COVID-19 vaccines in the immunocompromised population. In principle, there are no theoretical safety risks and no vaccine safety signals have been identified for vaccinated people with immunocompromise to date. Similar to responses following the administration of other inactivated vaccines in immunocompromised people, a reduced efficacy may occur following vaccination against COVID-19.
Our new reference page collates the various recommendations and guidance available for a broad group of immunocompromising conditions and therapies, as well as providing specific recommendations and/or links where available.
要了解更多信息，请点击以下链接：
MVEC: COVID-19 vaccines in people with immunocompromise
New immunisation reference page: Adverse events following COVID-19 immunisation
All immunisations are medications and all medications do have side effects. For each vaccine there is a known list of common or expected adverse events following immunisation (AEFI) and then a smaller list of serious side effects. Reporting significant adverse events is important to allow for signal detection and investigation as part of post-licensure vaccine safety monitoring.
Our new reference page explores what sort of reactions are common and expected following COVID-19 immunisation, and what sort of reactions warrant reporting.
For more information please refer to the following:
MVEC: COVID-19 vaccine adverse events
美国广播公司新闻：ATAGI 已告诉首相停止对 50 岁以下人群使用阿斯利康疫苗并使用辉瑞，但他们是谁？
The Australian Government’s recent decision to amend Australia’s vaccine program was based on the recommendation provided by ATAGI, following international evidence linking a rare blood-clotting condition to the AstraZeneca vaccine in younger people.
ATAGI is the Australian Technical Advisory Group on Immunisation. They provide recommendations to the Minister for Health regarding the National Immunisation Program (NIP) and other immunisation issues including immunisation research and immunisation policies, procedures and vaccine safety. Comprising of 14 medical experts, the group is co-chaired by Associate Professor Christopher Blyth, a specialist in paediatric infectious diseases, and Professor Allen Cheng, who specialises in epidemiology and public health.
This article summarises the role of ATAGI, including their recent recommendations to the Government regarding the AstraZeneca vaccine.
要阅读更多信息，请点击以下链接：
美国广播公司新闻：ATAGI 已告诉首相停止对 50 岁以下人群使用阿斯利康疫苗并使用辉瑞，但他们是谁？
For more information on ATAGI, please refer to our MVEC reference page:
New immunisation reference page: Thrombosis with thrombocytopenia syndrome
Thrombosis with thrombocytopenia syndrome (TTS) is a newly described serious condition which has been reported in people following receipt of dose 1 of COVID-19 AstraZeneca.
Our new reference page explores what is known about the syndrome including symptoms, rates of occurrence globally, risk factors and the types of investigations that should be performed in patients where TTS is suspected.
To read more please refer to the below link:
MVEC: Thrombosis with thrombocytopenia syndrome
有关原住民和托雷斯海峡岛民的 COVID-19 疫苗信息
这 National Aboriginal Community Controlled Health Organisation (NACCHO)
NCIRS have joined together to develop new resources on COVID-19 vaccines for Aboriginal and Torres Strait Islander people. This information includes frequently asked questions surrounding the safety and effectiveness of available vaccines, as well as the immunisation recommendations for special risk groups.To access these resources please follow the link below:
NACCHO: COVID-19 Vaccine Updates and Information
Further information on the immunisation recommendations for Aboriginal and Torres Strait Islander people can be found on our reference page:
新的免疫参考页面：COVID-19 每周疫苗更新
The rapid development of multiple COVID-19 vaccines globally has been a tremendous success story for public health. However, it can prove challenging to stay up to date with the increasing literature on various aspects of these vaccines. The COVID-19 weekly vaccine update summarises the data available on COVID-19 vaccines and includes: the specifications of COVID-19 vaccines, vaccine efficacy and effectiveness including against variants of concern; comorbidities and the elderly; vaccine safety; the pipeline for vaccine development; and the WHO SAGE timeline for vaccine authorisation. Each week, the document is updated and contains newly released information on the vaccines.
To subscribe to the update, email [email protected]
Alternatively you can access the update via our reference page below:
MVEC: COVID-19 weekly vaccine update
ATAGI-针对免疫功能低下患者的 COVID-19 疫苗指南
ATAGI have published recommendations for the vaccination of immune compromised patients with COVID-19 vaccines, Comirnaty™ and COVID-19 AstraZeneca.
COVID-19 vaccination is recommended for all immunocompromised people due to an increased risk of developing severe disease if infected with SARS-CoV-2. Administration of COVID-19 vaccines should be planned with the treating specialist and in some instances the timing of immune suppressive therapies may be altered to maximise immune responses to vaccination. Reducing the interval between COVID-19 vaccine doses to allow for planning of treatments can also be considered.
要查看这些建议，请参阅
- ATAGI – Provider guide to COVID-19 vaccination of people with immunocompromise
- ATAGI – COVID-19 vaccination decision guide for people with immunocompromise
For other information on the immunisation of immune compromised people please refer to:
New immunisation reference page: COVID-19 vaccines and allergy
Suspected hypersensitivity reactions, particularly non-urticarial skin rashes following immunisation, are common, however true vaccine allergy, where a person is contraindicated from being immunised with the same vaccine in the future, is rare (in most studies reported as less than 1 case per million doses).
Post-licensure surveillance of COVID-19 vaccines show anaphylaxis following administration of COVID-19 AstraZeneca occurring at similar rates to routine vaccines. Anaphylaxis following Comirnaty™ (Pfizer/BioNTech), while still extremely rare, occurs at a slightly higher rate of approximately 4.7 cases per million doses.
确诊的疫苗过敏通常需要咨询疫苗过敏专家，通常需要进行特定测试或在监督下进行疫苗挑战。
Find out more about allergies to COVID-19 vaccines, allergies to components of COVID-19 vaccines, and management of these allergies in our new immunisation reference page, COVID-19 疫苗和过敏.
Updated immunisation reference pages: Influenza vaccine recommendations and FAQ's
MVEC's recommendations for influenza vaccination in 2021 have been updated. Information contained in these pages includes dosing and brand advice (including information on cell-based vaccines), co-administration of influenza vaccines and other vaccines, recommendations in pregnancy and immunosuppression, as well as eligibility for funded doses.
Our FAQ's provide answers to commonly asked questions relating to influenza vaccines and their administration.
For more information please follow the links below: